Related references
Note: Only part of the references are listed.Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation
Alfredo Aram Pulini et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2021)
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies First Results From the RCT DUPLICATE Initiative
Jessica M. Franklin et al.
CIRCULATION (2021)
Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making
Shuxian Chen et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2021)
Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions
Caitlin Dodd et al.
BMJ GLOBAL HEALTH (2021)
Smart Safety Surveillance (3S): Multi-Country Experience of Implementing the 3S Concepts and Principles
Noha Iessa et al.
DRUG SAFETY (2021)
Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements
Hannah Sievers et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2021)
Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project
Jessica M. Franklin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Examining the Use of Real-World Evidence in the Regulatory Process
Brett K. Beaulieu-Jones et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Trial designs using real-world data: The changing landscape of the regulatory approval process
Elodie Baumfeld Andre et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions
Patricia A. Deverka et al.
VALUE IN HEALTH (2020)
Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?
Jim Slattery et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative
Lucinda S. Orsini et al.
VALUE IN HEALTH (2020)
Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review
Juan-Sebastian Franco et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Jason T. Hurwitz et al.
Journal of Managed Care & Specialty Pharmacy (2020)
Contextual equipoise: a novel concept to inform ethical implications for implementation research in low-income and middle-income countries
Nadine Seward et al.
BMJ GLOBAL HEALTH (2020)
Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi
Tisungane Mvalo et al.
PEDIATRIC BLOOD & CANCER (2019)
Use of real-world evidence for healthcare decision-making in the Middle East: practical considerations and future directions
Kasem S. Akhras et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2019)
Local ownership of health policy and systems research in low-income and middle-income countries: a missing element in the uptake debate
Kudakwashe Paul Vanyoro et al.
BMJ GLOBAL HEALTH (2019)
Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
Daniel C. Malone et al.
VALUE IN HEALTH (2018)
Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia
Aaloke Mody et al.
PLOS MEDICINE (2018)
Real-World Data Analytics Fit for Regulatory Decision-Making
Sebastian Schneeweiss et al.
AMERICAN JOURNAL OF LAW & MEDICINE (2018)
Real-World Evidence in the Real World: Beyond the FDA
Joan H. Krause et al.
AMERICAN JOURNAL OF LAW & MEDICINE (2018)
When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
Jessica M. Franklin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
The challenge of bridging the gap between researchers and policy makers: experiences of a Health Policy Research Group in engaging policy makers to support evidence informed policy making in Nigeria
Benjamin Uzochukwu et al.
GLOBALIZATION AND HEALTH (2016)
STATISTICAL METHODS FOR ACTIVE PHARMACOVIGILANCE, WITH APPLICATIONS TO DIABETES DRUGS
Lan Zhuo et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2014)
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review
J. Chilcott et al.
HEALTH TECHNOLOGY ASSESSMENT (2010)
Share Paper
